logo
logo

Q Biotics Appoints Stephen Doyle As Chief Executive Officer

Aug 05, 2024about 1 year ago

Position

Chief Executive Officer

Company

QBiotics Group Limited

Stephen Doyle
BrisbaneBiotechnologyHealth Care

Description

Stephen Doyle has been appointed as the Chief Executive Officer of QBiotics, effective from 2 September 2024. Stephen brings over 24 years of global pharmaceutical executive experience, with expertise in the discovery and development of new drugs, bringing them to market, and diversifying treatment options for patients.

Company Information

Company

QBiotics Group Limited

Location

Brisbane, Queensland, Australia

About

QBiotics is solving major health issues for humans and companion animals. We discover, develop and commercialise novel pharmaceuticals based on plant-derived cell-signalling molecules sourced from the Australian tropical rainforest, and underpinned by our discovery platform EcoLogic™. We simultaneously develop our products for the human and veterinary markets, delivering early to market veterinary products as well as real world animal data that informs and de-risks early stages of our human programmes. We currently have two leading programmes. The first is an oncology drug, tigilanol tiglate, with activity against a range of solid tumours. Tigilanol tiglate is now registered as a veterinary pharmaceutical, brand name STELFONTA®, and is marketed in the US, EU, UK and Australia. The drug is also currently in human Phase II clinical development. Our second programme is a pharmaceutical, EBC-1013, that addresses all the requirements for healing chronic and acute wounds. We have a very skilled and enthusiastic team of 61 employees.

Related People

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months